Clinical Trial Update: A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating ALE.P02 as monotherapy in adults with CLDN1+ solid tumors, including squamous cell carcinomas of the lung, head and nec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Squamous Cell Carcinoma
• Esophageal Squamous Cell Carcinoma
• Head and Neck Squamous Cell Carcinoma
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• ALE.P02 (ALE.P02)

Snippet

Sponsor: Alentis Therapeutics AG | Conditions: Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: RECRUITING